PSNCBAM-1: Difference between revisions

Latest revision as of 02:52, 11 December 2024

PSNCBAM-1 is a chemical compound that acts as a negative allosteric modulator of the cannabinoid receptor type 1 (CB1). It is of interest in the field of pharmacology and neuroscience due to its potential therapeutic applications in modulating the effects of cannabinoids.

Chemical Properties[edit]

PSNCBAM-1 is a synthetic compound with a specific chemical structure that allows it to interact with the CB1 receptor in a unique manner. The structure of PSNCBAM-1 is shown in the accompanying image. It is characterized by its ability to bind to an allosteric site on the CB1 receptor, distinct from the orthosteric site where endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol bind.

Mechanism of Action[edit]

As a negative allosteric modulator, PSNCBAM-1 decreases the activity of the CB1 receptor when it is activated by an agonist. This modulation can result in a reduction of the effects typically mediated by CB1 activation, such as appetite stimulation, analgesia, and psychoactive effects. By modulating the receptor's activity, PSNCBAM-1 offers a potential therapeutic approach to conditions where CB1 receptor activity is dysregulated.

Potential Therapeutic Applications[edit]

Research into PSNCBAM-1 has suggested several potential therapeutic applications:

Obesity and Metabolic Disorders: By reducing CB1 receptor activity, PSNCBAM-1 may help in managing obesity and related metabolic disorders, as CB1 activation is known to promote appetite and fat accumulation.
Pain Management: Modulating CB1 receptor activity can alter pain perception, offering a potential avenue for pain management without the psychoactive effects associated with direct CB1 agonists.
Addiction: PSNCBAM-1 may have potential in treating addiction by modulating the reward pathways influenced by CB1 receptor activity.

Research and Development[edit]

Ongoing research is focused on understanding the full pharmacological profile of PSNCBAM-1, its safety, efficacy, and potential side effects. Studies are also exploring its interactions with other components of the endocannabinoid system and its effects in various animal models.

Also see[edit]

@@ Line 1: / Line 1: @@
-[[File:PSNCBAM-1.png|thumb|PSNCBAM-1.png]] {{Short description|Chemical compound}}
+{{DISPLAYTITLE:PSNCBAM-1}}
-{{Infobox drug
+[[File:PSNCBAM-1.png|thumb|Chemical structure of PSNCBAM-1]]
-| image =
-| width =
+'''PSNCBAM-1''' is a chemical compound that acts as a [[negative allosteric modulator]] of the [[cannabinoid receptor type 1]] (CB1). It is of interest in the field of [[pharmacology]] and [[neuroscience]] due to its potential therapeutic applications in modulating the effects of cannabinoids.
-| alt =
-| caption =
+==Chemical Properties==
-| IUPAC name = 1-(4-Chlorobenzyl)-N-[(1S)-1-(3,4-dichlorophenyl)ethyl]-1H-indazole-3-carboxamide
+PSNCBAM-1 is a synthetic compound with a specific chemical structure that allows it to interact with the CB1 receptor in a unique manner. The structure of PSNCBAM-1 is shown in the accompanying image. It is characterized by its ability to bind to an allosteric site on the CB1 receptor, distinct from the orthosteric site where endogenous cannabinoids such as [[anandamide]] and [[2-arachidonoylglycerol]] bind.
-| CAS number = 1225843-86-6
-| PubChem = 53362045
+==Mechanism of Action==
-| ChemSpiderID = 29341824
+As a negative allosteric modulator, PSNCBAM-1 decreases the activity of the CB1 receptor when it is activated by an agonist. This modulation can result in a reduction of the effects typically mediated by CB1 activation, such as [[appetite stimulation]], [[analgesia]], and [[psychoactive effects]]. By modulating the receptor's activity, PSNCBAM-1 offers a potential therapeutic approach to conditions where CB1 receptor activity is dysregulated.
-| UNII =
-| KEGG =
+==Potential Therapeutic Applications==
-| ChEMBL = 2103872
+Research into PSNCBAM-1 has suggested several potential therapeutic applications:
-| synonyms =
-| C=24 | H=19 | Cl=3 | N=2 | O=1
+* '''Obesity and Metabolic Disorders''': By reducing CB1 receptor activity, PSNCBAM-1 may help in managing obesity and related metabolic disorders, as CB1 activation is known to promote appetite and fat accumulation.
-| molecular weight = 461.78
+* '''Pain Management''': Modulating CB1 receptor activity can alter pain perception, offering a potential avenue for pain management without the psychoactive effects associated with direct CB1 agonists.
-| smiles = C1=CC(=C(C=C1C(C)NC(=O)C2=NN(C3=CC=CC=C32)CC4=CC=C(C=C4)Cl)Cl)Cl
+* '''Addiction''': PSNCBAM-1 may have potential in treating addiction by modulating the reward pathways influenced by CB1 receptor activity.
-| StdInChI = 1S/C24H19Cl3N2O/c1-15(18-9-10-20(26)21(27)13-18)28-24(30)23-22-6-3-2-5-19(22)29(28)14-16-7-11-17(25)12-8-16/h2-13,15H,14H2,1H3,(H,28,30)
-| StdInChIKey = QXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQXQ
+==Research and Development==
+Ongoing research is focused on understanding the full pharmacological profile of PSNCBAM-1, its safety, efficacy, and potential side effects. Studies are also exploring its interactions with other components of the [[endocannabinoid system]] and its effects in various animal models.
+==Also see==
+* [[Cannabinoid receptor type 1]]
+* [[Endocannabinoid system]]
+* [[Allosteric modulation]]
+* [[Negative allosteric modulator]]
+{{Cannabinoid receptor modulators}}
+[[Category:Cannabinoid receptor modulators]]
+[[Category:Pharmacology]]
+[[Category:Neuroscience]]